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Abstract  
The aim of this study is to analyze the effectiveness and safety of direct‐acting antivirals (DAAs) in 
psychiatric patients with chronic hepatitis C (CHC). Secondary objectives included adherence and drug‐
drug interaction (DDIs) evaluations. Prospective observational comparative study carried out during 3 
years. Psychiatric patients were included and mental illness classified by a psychiatric team based on 
clinical records. Main effectiveness and safety variables were sustained virologic response (SVR) at 
posttreatment week 12 (SVR12) and rate of on‐treatment serious drug‐related adverse events (AEs), 
respectively. A total of 242 psychiatric and 900 nonpsychiatric patients were included. SVR12 by intention‐
to‐treat (ITT) analysis of psychiatric vs nonpsychiatric patients was 92.6% (95% confidence interval [CI], 
89.1‐96.1) vs 96.2% (95% CI, 94.9‐97.5) (P = .02). SVR12 by modified‐ITT analysis was 97.8% (95% CI, 
95.0‐99.3) vs 98.4% (95% CI, 97.5‐99.3) (P = .74). 92.2% of psychiatric patients with mental disorders 
secondary to multiple drug use (MDSDU) and 93.0% of psychiatric patients without MDSDU vs 96.2% of 
nonpsychiatric patients reached SVR12 (P = .05 and P = .20, respectively). The percentage of adherent 
patients to DAAs did not show differences between cohorts (P = .08). 30.2% of psychiatric patients and 
27.6% of nonpsychiatric patients presented clinically relevant DDIs (P = .47). 1.7% vs 0.8% of psychiatric 
vs nonpsychiatric patients developed serious AEs (P = .39); no serious psychiatric AEs were present. DAAs 
have shown a slightly lower effectiveness in psychiatric patients with CHC, as a result of loss of follow up, 
which justifies the need for integrated and multidisciplinary health care teams. DAAs safety, adherence, 
and DDIs, however, are similar to that of nonpsychiatric patients 
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1.Introduction 
The worldwide prevalence of hepatitis C virus (HCV) in the general population is estimated 
to be around 1.6%, which means that around 115 million people are chronically infected and that 
there may be more than 700 000 deaths a year, secondary to terminal liver disease.1 Several 
factors can affect the prevalence of HCV, such as the area of residence, age, sex, race, or 
comorbidities.2‐5 Several epidemiological studies have analyzed the presence of HCV in patients 
with psychiatric illnesses (schizophrenia, bipolar disorder, substance use disorder, etc), 
evidencing a higher prevalence than in the general population.6‐9 On the other hand, in parallel 
with liver disease, HCV can cause extrahepatic manifestations, among which are neurological 
and psychiatric diseases.10‐13 Therefore, the treatment of chronic HCV disease in the psychiatric 
population is a priority which must be addressed by multidisciplinary clinical teams promoting 
accessibility and continuity to antiviral treatment to guarantee the best results, in terms of safety 
and therapeutic effectiveness.14‐17  
Interferon (IFN) or pegylated (Peg)‐IFN alone, or associated with ribavirin (RBV), was 
initially used to treat chronic hepatitis C (CHC). In 2011, two first‐generation direct‐acting 
antivirals (DAAs) were approved for HCV chronic infection in combination with Peg‐IFN and 
RBV, telaprevir, and boceprevir. These IFN‐based treatments were contraindicated in a great 
majority of psychiatric patients. So, treatment of CHC in many psychiatric patients has been 
deferred until the authorization of the current second‐generation DAAs that, at present, constitute 
the gold standard of CHC treatment due to the high effectiveness and safety rates observed in 
clinical trials and in real‐life studies.18 Moreover, psychiatric HCV patients may present 
particular characteristics related to the basal pathology or pharmacological treatment (adherence 
to antiviral treatment, drug‐ medication interactions between DAAs and concomitant treatment, 
and increase of neurological or psychiatric adverse effects), social factors, or interaction with the 
health system that can condition the success of DAAs‐based treatment observed in the general 
population.19 Moreover, pivotal clinical trials for DAA authorization by the European or 
American drugs regulatory agencies pinpointed in many cases (sofosbuvir [SOF], daclatasvir 
[DCV], velpatasvir [VEL], ledipasvir [LDV], voxilaprevir, glecaprevir, pribentasvir, etc), the 
presence of current or past psychiatric illness or drug/alcohol consumption as exclusion 
criteria.20‐28 Likewise, real‐life studies on the use of DAAs in psychiatric patients are virtually 
nonexistent or are limited to a very small number of antivirals or psychiatric patient subgroups. 
The main objective of this study is to evaluate the effectiveness and safety in the real clinical 
practice of DAAs in psychiatric HCV patients. Secondary objectives include the analysis of 
psychiatric conditions on adherence to antiviral therapy and the assessment of the incidence of 
clinically significant interactions between antiviral and concomitant treatment in psychiatric 
HCV‐infected patients. 
2.Methods 
2.1 Study design and patient selection 
This is a unicentric observational prospective cohort study of HCV‐ infected patients who 
started DAAs‐based antiviral treatment during 3 years in our institution and who had reached 
week 12, post end of the treatment. Adult HCV‐infected patients, treatment‐naïve, or treatment‐
experienced to peg‐INF ± RBV, in all fibrosis stages (F0‐F4), including patients with 
decompensated cirrhosis or portal hypertension, human immunodeficiency virus (HIV) 
coinfected patients, or liver transplant patients were included. HCV‐infected patients were 
divided into two cohorts at baseline: psychiatric and nonpsychiatric patients. The inclusion in 
the cohort of psychiatric patients was established by the hospital psychiatry team, based on the 
baseline diagnosis of mental illness, current follow up in Outpatient Psychiatry Unit, Mental 
Health Unit, or Centre for Drug Addiction, hospital admissions in the Department of Psychiatry 
and pharmacological treatment for the psychiatric disorder. The diagnosis of mental illness was 
classified based on the International Classification of Diseases‐10, Classification of Mental and 
Behavioral Disorders.29 Antiviral treatment selection and prescription decisions corresponded to 
the hospital infectologist or hepatologist, under usual clinical practice conditions valid during 
the study period, according to the reference treatment guidelines at the time of initiation of 
antiviral treatment.30,31  
Adherence rates were made following continuous measurement of the medication acquisition 
method,32 during monthly visits to the Hospital Pharmacy Service where the study was 
conducted, from the beginning to the end of the treatment. To compare the number of adherent 
patients, both cohorts have been stratified into four levels of adherence to DAAs (very high: 
95%‐100%; high: 90%‐94%; mild: 85%‐89%; and moderate: <85%); additionally, a statistical 
analysis comparing the integrated and stratified distribution of adherent patients in both cohorts 
have been carried out. Drug‐drug interactions (DDIs) were identified by the clinical team 
(clinical pharmacists, hepatologists, and infectologists) using the Hep Drug Interactions database 
of the University of Liverpool,33 recommended as a reference by the European Association for 
the Study of the Liver.31 Where no information was available, Lexicomp Drug Interactions,34 
IBM Micromedex,35 analysis of pharmacokinetic parameters available in the technical data sheet, 
and consultation with the DAA manufacturing laboratory were employed. Regardless of the 
source of information on DDIs consulted, clinically significant DDIs were considered those that 
required clinical or therapeutic action to achieve the therapeutic objective of antiviral treatment 
as well as to achieve or maintain the therapeutic objectives and safety of concomitant treatment; 
particularly, in the case of Hep Drug Interactions database of the University of Liverpool, 
interactions that contraindicated the simultaneous use of the DAAs and the concomitant drug 
(“contraindicated”: red flag) and those that required a specific clinical action (“potential”: amber 
flag) were included. 
2.2 Effectiveness and safety variables 
Pharmacological treatment adherence, DDIs, effectiveness, and safety follow up were carried 
out through SiMON, an artificial intelligence monitoring system for HCV‐infected patients on 
antiviral treatment, that records effectiveness and safety events from clinical data.36 Additional 
data regarding hospitalizations, admissions in the emergency room, outpatient consultations, or 
interconsultation to Psychiatry Department have been collected from patients' electronic clinical 
records. 
HCV viral load (defined as the ribonucleic acid (RNA) HCV in plasma) was determined 
using the real‐time polymerase chain reaction technique with the COBAS AmpliPrep platform 
from Roche. The kit is the HCV Quantitative Test, version 2.0. The limits of detection and 
quantification in plasma (there is no significant difference in the serum) were 11 IU/mL (10‐13 
IU/mL; 95% confidence interval [CI]) for the lower limit of detection (LOD) with a 95% positive 
result rate and 15 IU/mL for LOD with positive results. Viral load determinations were made at 
the baseline, end of treatment, and 12 weeks after the antiviral treatment was completed. 
Transient elastography was used for the staging of liver fibrosis (FibroScan), stratifying patients 
according to stiffness results in fibrosis F0‐F1 (14.4 kPa in HCV monoinfected patients and 
>14.0 kPa in HIV coinfected patients). 
The primary effectiveness endpoint was the sustained virologic response 12 (SVR12), 
defined as RNA‐HCV undetectable 12‐weeks post end of the treatment. Secondary efficacy 
variables were null response (lack of RNA‐HCV undetectability during DAAs treatment) and 
recidivant (RNA‐HCV detectable 12‐weeks posttreatment in a patient with RNA‐ HCV 
undetectable at the end of treatment). The primary safety endpoint was the rate of on‐treatment 
serious drug‐related adverse events (AEs); secondary variables included on‐treatment drug‐
related AEs, DAA or concomitant treatment withdrawal due to AEs, emergency room admission, 
hospitalization, or outpatient consultation secondary to drug‐related AEs and death secondary to 
serious drug‐related AEs. Specific identification of psychiatric adverse effects, potentially 
secondary to antiviral treatment or hospitalizations in Psychiatry Service, secondary to 
exacerbations of psychiatric illness in the subgroup of patients with major psychiatric disorders, 
were made by comparing its incidence during two periods equal to the duration of antiviral 
treatment before and after the start date thereof. 
The main variables related to secondary objectives of this study were the percentage of 
adherence to antiviral treatment and the percentage of clinically significant DDIs. 
2.3 Statistical analysis 
The intention‐to‐treat (ITT) evaluable population included all patients who took at least one 
dose of the prescribed treatment. Modified intention‐to‐treat (mITT) evaluable population 
included all ITT evaluable population but excluded patients without quantification of RNA‐HCV 
12‐weeks posttreatment for reasons other than treatment failure Baseline variables 
(demographics, clinical, histological and laboratory values, and frequencies) were evaluated by 
ITT analysis. Effectiveness variables were analyzed by an mITT and ITT analysis. Safety 
variables were calculated by ITT analysis. Quantitative variables were expressed as mean ± 
standard deviation (SD) and were analyzed using Student t test or the Mann‐Whitney U test, 
according to data distribution. Qualitative variables were expressed as count and percentage, 
with CI at 95%, and were compared using a χ2 or Fisher's exact test. Primary endpoints were 
expressed as a percentage and an exact 95% binomial CI. To detect differences between cohorts 
related to psychiatric illness influence on effectiveness variables, univariate and multivariate 
analyses were performed. Statistically significant results were considered when P ≤ .05. 
Statistical analysis (percentage, mean, median, SD, CI, univariate and multivariate analysis, 
Student's t test, Mann‐Whitney U test, χ2 test, and Fisher's exact test) was carried out using the 
Epidat 4.2 program. 
2.4 Ethics approval 
This study complies with the Declaration of Helsinki Good Clinical Practice. It was classified 
in 2015 as “Observational Post‐Authorization Study with Human Medicines” by the Spanish 
Agency of Medicines and Health Products, and authorized by the Clinical Research Ethics 
Committee (CREC) of the Regional Health Service (2015). Patients signed an informed consent 
approved by the CREC for their participation in the study and all their data were anonymized. 
3.Results 
3.1 Baseline patient demographics and characteristics 
A total of 1142 adult patients started antiviral treatment during the study period at our 
institution, of which 242 were psychiatric patients (21.2%; 95% CI, 18.8‐23.6) and 900 were 
nonpsychiatric patients: they constitute the ITT population. Of these 1142 patients, 33 patients 
(13/242 psychiatric and 20/900 nonpsychiatric patients) who completed the antiviral treatment 
did not perform the HCV viral load determination 12 weeks after the end of treatment (P = .02): 
they constitute the mITT population (229 psychiatric and 880 nonpsychiatric patients). The 
psychiatric patients were mostly men under 65 years of age, with a lower percentage of patients 
older than 65 years (P < .01). The majority of psychiatric patients were HCV genotype‐1 
monoinfected, although they showed a higher HIV‐ coinfection rate vs nonpsychiatric patients 
(22.3% vs 11.2%; P < .01 Also, the psychiatric cohort had low HCV viral loads (<6.1 log 
IU/mL),with a homogenous distribution between the high and low degree of liver fibrosis (F3‐
F4: 55.4%; 95% CI, 48.9‐61.9) and mostly noncirrhotics (65.3%; 95% CI, 59.1‐71.5). 75.6% 
(95% CI, 70.0‐81.2) of psychiatric patients were naïve to antiviral treatment and the majority of 
experienced patients had a recurrence to previous antiviral treatment based on Peg‐IFN ± RBV. 
Only 2.5% of cirrhotic patients had suffered hepatic decompensation before the start of antiviral 
treatment or had experienced a liver transplant. LDV/ SOF ± RBV and DCV + SOF ± RBV were 
by far the most prescribed DAAs in both cohorts; the prescription of antiviral treatments 
containing at least one HCV protease inhibitor (PI) was 17.8% (95% CI, 12.7‐22.8) among 
psychiatric patients and 32.0% (95% CI, 29.9‐35.1) among nonpsychiatric patients (P < .01); 
more psychiatric patients required antiviral treatment durations of 24 weeks vs those who ere 
nonpsychiatric (21.5% vs 13.8%; P < .01). Table 1 shows the main baseline characteristics and 
antiviral treatment of the two cohorts, as well as the statistical differences between the two 
subpopulations. 
Among psychiatric patients, the analysis of the diagnoses reveals that 61.6% of them (95% 
CI, 55.2‐67.9) presented one psychiatric disorder and 32.2% (95% CI, 26.1‐38.3) of them 
presented two baseline psychiatric disorders, namely mental and behavioral disorders due to 
multiple drug use (MDSDU) and use of other psychoactive substances and depressive episode 
or recurrent depressive disorders. 68.2% (95% CI, 62.1‐74.3) of the patients were at the time of 
the start of antiviral treatment with at least two psychiatric medications, among which 
benzodiazepines, antidepressants, long‐acting antipsychotics, and neuroleptics stand out. Table 
2 shows the classification of mental and behavioral disorders and psychiatric drugs of the 
psychiatric study population and its frequency in the psychiatric cohort. 
The average percentage adherence to antiviral treatment of psychiatric vs nonpsychiatric 
patients was 99.05% ± 1.48% vs 99.56% ± 1.27%, respectively (P < .01). Comparatively, the 
stratified distribution of adherent patients to antiviral treatment in psychiatric vs nonpsychiatric 
patients (level by level) was: very high 95.9% (232/ 242) vs 98.3% (885/900) (P = .04); high 
2.9% (7/242) vs 1.3% (12/900) (P = .16); mild 0.8% (2/242) vs 0.1% (1/900) (P = .22); and 
moderate 0.4% (1/242) vs 0.2% (2/900) (P = .85). The integrated analysis of adherent patients 
(all levels) to DAAs between both cohorts did not show statistically significant differences (P = 
.08). 
In relation to the DDIs identified, 30.2% (95% CI, 24.2‐36.2) of psychiatric patients and 
27.6% (95% CI, 24.6‐30.5) of nonpsychiatric patients presented clinically relevant DDIs (P = 
.47). Among psychiatric patients, the main therapeutic group that generated clinically significant 
DDIs was A02 (drugs for acid‐related disorders) with 11.6% of affected patients, followed by 
N05 (psycholeptics) with 8.3% of cases; among nonpsychiatric patients, also the therapeutic 
group A02 was the main one but followed by C09 (agents acting on the renin‐ angiotensin system 
) with 6.7% of affected patients. Regarding concomitants drugs, omeprazole, paliperidone, and 
alprazolam among psychiatric patients and omeprazole, amlodipine, and atorvastatin among 
nonpsychiatric patients were the main concomitants medications involved in DDIs detection. 
DAAs mainly involved in the development of clinically significant DDIs were 
paritaprevir/ombitasvir/ritonavir + RBV (PTV/OBV/RTV + RBV) and PTV/OBV/RTV + 
dasabuvir ± RBV among psychiatric and nonpsychiatric patients, respectively. The incidence of 
DDIs if antiviral treatment containing or not PIs was 40.6% vs 28.6% in psychiatric patients (P 
= .24) and 34.9% vs 24.1% in nonpsychiatric patients (P < .01). As a result of DDIs detection 
among psychiatric patients, the therapeutics interventions carried out were distributed as follows: 
38.3% administration schedule adjustment, 31.5% effectiveness (eg, blood pressure) and/or 
safety (eg, renal function) closer clinical monitoring, 19.2% dosage regimen adjustment (with 
pharmacokinetic drug monitoring in 5 cases), 9.6% temporary suspension before DAA treatment 
(four patients with oxcarbamazepine, two metamizole, and one rosuvastatin), and one definitive 
substitution before DAA treatment (topiramate in one patient with oxcarbamazepine). No 
concomitant medication required suspension during treatment with DAAs. 
A total of 33 psychiatric patients were on treatment with anticonvulsants; 10 with topiramate, 
6 with sodium valproate, 5 with oxcarbamazepine, and the remaining 12 with another 6 different 
anticonvulsants. Of all of them, 20 were treated with LDV/SOF ± RBV, 7 with DCV + SOF ± 
RBV, and 3 of them with other DAAs. Five patients with clinically significant baseline DDIs 
between DAAs and oxcarbazepine (three treated with LDV/SOF, one with VEL/SOF, and one 
with DCV + SOF) were identified; as previously underlined, in four of these patients, temporary 
suspension of oxcarbamazepine was indicated during antiviral treatment (temporarily substituted 
by sodium valproate in one patient), and in one case, the indefinite replacement of oxcarbazepine 
with topiramate was indicated in a patient also under concomitant treatment with lacosamide. 
These modifications in the antiepileptic treatment did not result in a loss of neurological control 
of the disease. No other clinically significant interactions were identified between DAAs and 
anticonvulsant treatment. No patient has been excluded from the study or analysis because of 
concomitant medications. Table 3 shows the therapeutic groups and concomitant drugs mainly 
involved in the development of clinically significant DDIs, as well as the most affected DAAs, 
for psychiatric and nonpsychiatric patients. 
3.2 Effectiveness outcomes 
The SVR12 by ITT analysis of psychiatric vs nonpsychiatric patients was 92.6% (95% CI, 
89.1‐96.1) vs 96.2% (95% CI, 94.9‐97.5) (P = .02); SVR12 by mITT analysis was 97.8% (95% 
CI, 95.0‐99.3) vs 98.4% (95% CI, 97.5‐99.3), (P = 0.74), respectively (Figure 1). 92.2% of 
psychiatric patients with mental disorders secondary to MDSDU and 93.0% of psychiatric 
patients without MDSCU vs 96.2% of nonpsychiatric patients reached SVR12 (P = .05 and P = 
.20, respectively). SVR12 data were not available for the 5.4% of psychiatric vs 2.2% of 
nonpsychiatric patients in the ITT analysis (P = .02); more specifically, 2.2% of nonpsychiatric 
patients vs 7.0% of psychiatric patients with MDSDU (P < .01) and vs 3.0% of psychiatric 
patients without MDSDU (P = .89) did not resort to the analytical determination 12 weeks after 
the end of treatment. SVR12 in presence vs absence of the next diagnoses was: depressive 
disorders 93.4% vs 92.2% (P = .97), anxiety disorders 92.2% vs 100.0% (P = .17), and 
schizoaffective disorders disorders 91.8% vs 100.0% (P = .16). 
  
 
Table 1 Demographic and virological characteristics of the study population 
Characteristic 
Psychiatric 
patients   
n = 242 (21.2%) 
Nonpsychiatric patients  n = 900 
(78.8%)   
P 
Males, % (n) 69.4% (168) 62.8% (565) .07 
Age, mean (years ± SD) 52.8 ± 10.0 58.72 ± 13.1 <.01 
Age ≥ 65 y, % (n) 9.9% (25) 33.2% (299) <.01 
HCV genotype    
1 60.3% (146) 73.3% (660) <.01 
2 5.0% (12) 5.7% (51) .79 
3 21.1% (51) 12.2% (110) <.01 
4 13.6% (33) 8.8% (79) .03 
HIV coinfection, % (n) 22.3% (54) 11.2% (101) <.01 
Fibrosis stage, % (n)    
F0‐F1 12.4% (30) 18.1% (162) .05 
F2 32.2% (78) 31.2% (281) .82 
F3 20.7% (50) 24.3% (219) .27 
F4 34.7% (84) 26.4% (238) .01 
Previous clinical decompensation, % (n) 3.3% (8) 3.3% (30) .86 
CTP classification, % (n)    
A (5‐6) 97.9% (237) 99.1% (892) .23 
B (7‐9) 2.1% (5) 0.9% (8) .06 
C (>9) 0.0% (0) 0.0% (0) .99 
Hepatocellular carcinoma, % (n) 2.5% (6) 3.3% (30) .64 
Estimated glomerular filtration rate < 60 
mL/min, % (n) 
5.4% (13) 6.7% (60) .56 
Previous antiviral treatment. % (n)    
Naïve 75.6% (183) 73.6% (662) .57 
IFN‐based treatment‐experienced 24.4% (59) 26.4% (238) .57 
DAAs    
LDV/SOF ± RBV 54.1% (131) 48.1% (433) .11 
DCV + SOF ± RBV 20.2% (51) 12.2% (110) <.01 
PTV/OBV/RTV + DBV ± RBV 7.4% (18) 24.3% (219) <.01 
SMV/SOF ± RBV 6.6% (16) 2.1% (19) <.01 
ELB/GRZ 3.7% (9) 5.6% (50) .33 
VEL/SOF ± RBV 3.3% (8) 2.4% (22) .60 
PTV/OBV/RTV + RBV 2.1% (5) 2.2% (20) .92 
SOF + RBV 1.7% (4) 3.0% (27) .37 
Treatment duration, % (n)    
8 wk 7.0% (17) 10.0% (90) .20 
12 wk 70.3% (170) 76.0% (684) .08 
16 wk 1.2% (3) 0.2% (2) .11 
24 wk 21.5% (52) 13.8% (124) <.01 
RBV addition, % (n) 26.9% (65) 21.8% (196) .11 
 
Abbreviations: CTP, child‐pugh‐turcotte; DBV, dasabuvir; DCV, daclatasvir; ELB, elbasvir; GRZ, grazoprevir; HCV, 
hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; LDV, ledipasvir; OBV, ombitasvir; PTV, 
paritaprevir; RBV, ribavirin; RTV, ritonavir; SD, standard deviation; SMV, simeprevir; SOF, sofosbuvir; VEL, velpatasvir 
  
95.6% of psychiatric patients with a single diagnosis of mental disorder reached SVR12, 
compared to 90.8% of psychiatric patients with at least two diagnoses of mental disorders (P = 
.27). 93.9% of psychiatric patients on treatment with a single psychiatric drug reached SVR12, 
compared to 89.6% of psychiatric patients with at least two psychiatric drugs (P = .35). No 
statistically significant differences were observed in SVR12 due to viral genotype (P > .15). 
SVR12 in cirrhotic patients was 92.2% vs 94.6% (P = .78) in psychiatric vs nonpsychiatric 
patients. Table 4 shows primary andsecondary effectiveness endpoints. Table5 shows the results 
ofmultivariate analysis on SVR12. 
Table 2 Classification of mental and behavioral disorders and psychiatric 
drugs of the psychiatric study population 
 
Category % (n)  
Mental and behavioral disorders 
Mental and behavioral disorders due to 
multiple drug use and use of other 
psychoactive substances 
58.7%(142)
Depressive episode or recurrent depressive 
disorders 
25.6% (62)
Phobic anxiety disorders or other anxiety 
disorders 
15.7% (38)
Schizophrenia, schizoaffective disorders or 
schizotypal disorders 
14.9% (36)
Disorders of adult personality and behavior 14.1% (34)
Bipolar affective disorders 3.3% (8) 
Habit and impulse disorders 2.5% (6) 
Others 10.3% (25)
Number of mental and behavioral disorders 
perper patient 
1 Mental and behavioral disorders 
61.6%(149) 
2 Mental and behavioral disorders 32.2% (78) 





Long‐acting antipsychotics 37.6% (91)
Neuroleptics 35.9% (87)
Anticonvulsants 13.6% (33)
Lithium 2.1% (5) 
Other psychiatric drugs 15.3% (37)
Number of psychiatric drugs per patient 
1 Psychiatric drug 
31.8% (77) 
2 Psychiatric drugs 34.3% (83) 
3 Psychiatric drugs 21.9% (53) 
>3 Psychiatric drugs 11.9% (29) 
 
3.3 Safety outcomes 
The rate of any degree AEs secondary to DAAs treatment for psy-chiatric and nonpsychiatric 
HCV patients was 59.1% (95% CI, 52.7%‐65.5%) and 56.4% (95% CI, 53.2%‐59.7%), 
respectively (P = .51).Meanwhile, 1.7% (95% CI, 0.5%‐4.2%) vs 0.8% (95% CI, 0.2%‐1.4%) 
ofpsychiatric vs nonpsychiatric patients developed serious AEs(P = .39); three psychiatric 
patients manifested severe headaches(which responded to the use of nonsteroidal analgesics) and 
onepatient presented constipation which required the use of a rectalenema; no serious adverse 
psychiatric effects were present in bothcohorts. Beyond this, 5.4% (95% CI, 2.3‐8.4) vs 6.3% 
(95% CI,4.7‐8.0I) of psychiatric vs nonpsychiatric patients developed moderate AEs (P = .69), 
of very similar nature between the two co-horts, highlighting fatigue/asthenia, pruritus, and 
headache. In relation to severe or moderate adverse effects of a psychiatric orneurological nature, 
one psychiatric patient developed anxiety duringantiviral treatment against nine nonpsychiatric 
patients who mani-fested insomnia (four), irritability (three), depressive state (one), andanxiety 
(one), although without statistically significant differences (P = .63). No patient from both 
cohorts required treatment with-drawal (antiviral or concomitant) as a consequence of the 
develop-ment of serious AEs. 0.8% vs 0.7% of psychiatric patients vsnonpsychiatric patients 
went to the emergency room as a result ofAEs to antiviral treatment (P = .87). No patient required 
hospitalization or died due to serious AEs. Table4 shows the main safety data. 
4.Discussion 
CHC treatment has undergone a radical change with the introductionof second‐generation 
DAAs due to its very high efficacy and safetyrates that have positioned them as treatments of 
choice in generalpopulation HCV‐infected patients.30,31DAAs have also provided anopportunity 
for virological cure in populations where the use ofinterferon‐based treatments (associated with 
RBV and/or first‐generation DAAs) was contraindicated or had to be used with cau-tion. This is 
the case of psychiatric HCV‐infected patients, wheretreatments based on IFN caused a high rate 
of therapeutic with-drawal, null virological responses, or intolerance37; in these patients,the 
difficulty in antiviral treatment accessing had clinical con-sequences both to hepatic and 
extrahepatic level, such as the in-cidence of psychiatric symptoms due to the action of HCV on 
centralnervous system.12,38In fact, DAAs have meant greater access for thepsychiatric population 
to antiviral treatment against HCV.39. 
The present study analyses the effectiveness and safety in realpractice of treatments with 
second‐generation DAAs in a large groupof patients infected with HCV and with mental illness, 
compared tononpsychiatric patients. A high percentage of patients of the popu-lation analyzed 
in this study have a psychiatric illness; a higher per-centage than that observed in European 
epidemiological studies,40although justified by the prevalence of HCV infection in the popu-
lation with mental illness.41,42These data are probably due to thefact that the treatment of HCV 
in patients with mental illness hasbeen deferred for the reasons mentioned above. This may also 
be thereason for the higher percentage of cirrhotic patients compared tononpsychiatric patients 
in the analyzed population. Also, the psy-chiatric subpopulation of this study is significantly 
younger, probablydue to earlier diagnoses linked to contact with the health systemmotivated to 
psychiatric diagnosis or high‐risk viral contagionbehaviors.43There is also a higher rate of HIV 
coinfection in psychiatricpatients compared to nonpsychiatric patients, already identified 
inprevious studies,42although this will not affect the effectiveness andsafety results in real 
clinical practice if adequate control of basal in-teractions with antiretroviral treatment is carried 
out.44In addition,although longer durations of antiviral treatment are observed in psychiatric 
patients, this is justified by the higher percentage of cir-rhotic patients in this study subgroup, as 





Table 3 Main therapeutic groups, concomitant drugs, and DAAs involved in clinically significant DDIs 
Psychiatric patients  Nonpsychiatric patients P 
Therapeutic group    
 







N05 psycholeptics 8.3% 3.7% <.01
C09 agents acting on the Ren‐An system 3.3% 6.7% .07
N03 anticonvulsants 2.9% 0.1% <.01
C10 lipid modifying agents 2.1% 5.2% .06
C08 calcium channel blockers 1.7% 3.9% .13






Paliperidone 3.3%  0.0% <.01 
Alprazolam 2.9%  0.8% .04 
Oxcarbamazepine 2.1%  0.0% <.01 
Amlodipine 1.7%  3.3% .25 
Atorvastatin 0.8%  2.7% .14 
Pravastatin 0.8%  0.4% .82 
DAAs 
PTV/OBV/RTV + RBV 60.0% 20.0% .22
SOF + RBV 50.0% 22.2% .57
PTV/OBV/RTV + DBV ± RBV 38.9% 38.8% .81
LDV/SOF ± RBV 38.9% 26.8% .01
VEL/SOF ± RBV 37.5% 18.8% .65
ELB/GRZ 33.3% 24.0% .86
SMV/SOF ± RBV 12.5% 10.5% .73
DCV/LDV ± RBV 3.9% 17.2% .04
Figure 1 SVR12 in psychiatric vs nonpsychiatric HCV‐infected patients according to statistical analysis. HCV, hepatitis 




Table 4 Effectiveness and safety of direct‐acting antivirals based on psychiatric disorder presence 
Global virologic response (mITT analysis)    
SVR12 97.8% (224) 98.4% (866) .74 
Null responder 0.0% (0) 0.5% (4) .69 
Recidivant 2.2% (5) 1.1% (10) .37 
No data 5.7% (13) 2.3% (20) .01 
Global virologic response (ITT analysis) 
SVR12 
92.6% (224) 96.2% (866) .02 
Null responder 0.0% (0) 0.4% (4) .67 
Recidivant 2.1% (5) 1.1% (10) .40 
No data 5.4% (13) 2.2% (20) .02 
Virologic response by mental (ITT analysis) 
Mental and behavioral disorders due to 
multiple drug use and use of other 
psychoactive substances 
92.2% (131) 96.2% (866) .05 
Depressive episode or recurrent depressive 
disorders 
93.5% (35) 96.2% (866) .48 
Phobic anxiety disorders or other anxiety 
disorders 
94.7% (36) 96.2% (866) .97 
Schizophrenia, schizoaffective disorders or 
schizotypal disorders 
97.2% (35) 96.2% (866) .89 
Disorders of adult personality and behavior 94.2% (34) 96.2% (866) .86 
Bipolar affective disorders 75% (6) 96.2% (866) .03 
Habit and impulse disorders 83.3% (5) 96.2% (866) .57 
Any grade drug‐related AEs 59.1% (143) 56.4% (508) .51 
Serious drug‐related AEs 1.7% (4) 0.8% (7) .39 
Emergency room admission due to serious drug‐
related AEs 
0.8% (2) 0.7% (6) .87 
On‐treatment hospitalization due to serious drug‐
related AEs 
0.0% (0) 0.0% (0) >.99 
Death due to serious drug‐related AEs 0.0% (0) 0.0% (0) >.99 
Any grade AEs with global incidence > 2.0% 
Fatigue/asthenia 40.1% 34.0% .09 
Headache 23.5% 18.6% .10 
Dizziness 4.5% 3.6% .60 
Gastrointestinal upset 3.7% 3.6% .94 
Anxiety 3.7% 1.1% .01 
Insomnia 3.3% 6.3% .10 
Drowsiness 2.9% 1.7% .33 
Nausea 3.3% 4.2% .65 
Diarrhea 3.3% 2.6% .68 
Pruritus 2.9% 7.4% .02 
Dry skin and mucous membranes 2.1% 1.7% .89 
Constipation 2.1% 1.1% .40 
Appetite disorders 2.1% 0.9% .23 
Musculoskeletal pain 1.2% 2.0% .61 
Abbreviations: AEs, adverse events; ITT, intention to treat; mITT, modified 
intention to treat; SVR12, sustained virologic response 12. 
Psychiatric patients % 
(n) 
Nonpsychiatric patients % 
(n) 
P 
Table 5 Multivariate analysis on SVR12 
Variable OR 95% CI  P 
Naïve 0.99 0.51 1.91 .98 
Genotype 2 1.22 0.28 5.23 .79 
Genotype 3 0.53 0.26 1.08 .08 
Genotype 4 1.44 0.43 4.83 .56 
Cirrhosis 0.72 0.39 1.32 .29 
Psychiatric 0.51 0.27 0.96 .04 
Abbreviations: CI, confidence interval; OR, odds ratio; SVR12, sustained virologic response 12. 
In relation to the antiviral treatment used, a lower prescription of DAAs based on PIs is observed 
in the psychiatric population, because the PIs are the drugs with the highest degree of clinically 
significant interactions with the psychiatric treatment, as we have confirmed in the results of this 
study. The adequacy of the baseline antiviral treatment in psychiatric and nonpsychiatric patients in 
this study has allowed no statistically significant differences to be observed in the percentage of 
clinically significant interactions between both subgroups. Regarding to therapeutic groups and 
concomitant medication, most frequently involved in clinically significant DDIs, it is observed that 
although antacids are the most affected medications (as in the nonpsychiatric population), specific 
therapeutic groups widely used in psychiatric patients (psycholeptics or anticonvulsants) stand out 
for their high degree of interaction with DAAs. This fact is confirmed at the level of concomitant 
medication, since it is observed that paliperidone or alprazolam have more clinically significant 
DDIs in the group of psychiatric patients when compared to nonpsychiatric patients. In relation to 
DAAs involved in the development of DDIs, it is important to note that in the group of psychiatric 
patients LDV/SOF ± RBV and DCV + SOF ± RBV generate more DDIs than in the cohort of 
nonpsychiatric patients; in parallel, the presence of PIs among antiviral treatment in psychiatric 
patients does not affect the development of DDIs, unlike what happens among nonpsychiatric 
patients; these differences can be explained on the basis that SOF (polymerase inhibitor antiviral, 
not PI) generates more interactions with psycholeptics and anticonvulsants, which are therapeutic 
groups more prescribed in the cohort of patients with mental disorders in this study. It is also 
noteworthy that a very significant number (almost one‐third) of psychiatric patients required the 
suspension or dose adjustment of concomitant treatment in the presence of a clinically significant 
DDI with the antiviral treatment. In this sense, of particular interest is the management of psychiatric 
patients treated with anticonvulsants, since certainly this is one of the most difficult groups to treat 
with DAAs given the magnitude of DDIs with all the older anticonvulsants; in this study, only 
oxcarbamazepine presented clinically significant DDIs at baseline, that were resolved, without 
neurological consequences, by temporary or definitive replacement of this antiepileptic. 
The importance of adherence to antiviral treatment based on DAAs is an aspect that international 
treatment guidelines recommend to maximize the effectiveness of the treatment.30,31 However, there 
is no clearly established consensus on the percentage of adherence above which a patient can be 
considered “adherent.” In this study, as had already been evaluated in previous studies,45,46 no 
clinically significant differences were observed in relation to the global adherence to antiviral 
treatment between psychiatric and nonpsychiatric patients (rates higher than 99%, in both cases). 
Moreover, although the number of patients with very high adherence (≥95%) is greater in the cohort 
of nonpsychiatric patients, when statistically analyzing the overall distribution of the four levels of 
DAAs adherence, no significant differences were observed. 
The ITT results of this study reveal a lower DAAs effectiveness in real clinical practice in 
psychiatric vs nonpsychiatric patients; less effective than that observed in mITT analysis. This is 
because more psychiatric patients quit clinical follow up after the completion of antiviral treatment 
and, therefore, it is not possible to determine SVR12. The results of our study show that these follow 
up losses in the group of psychiatric vs nonpsychiatric patients must be attributed to MDSDU‐
patients and not to patients with other psychiatric disorders. These results reinforce the importance 
of care in integrated multidisciplinary health systems for the treatment of psychiatric patients, as is 
currently recommended, since they promote clinical adherence and improve the likelihood of 
achieving SVR in this subgroup of patients.47‐49 The results of our study are in line with those 
reported in similar studies, in which the SVR12 reached with DAAs in patients with psychosocial 
comorbid conditions, substance use, mental health disorders, psychiatric disease or illicit drug use, 
was found among the 90%‐96%.50‐54 Of particular interest are the results observed by Back et al55 in 
an integrated analysis of the use of glecaprevir/ pibrentasvir in psychiatric vs nonpsychiatric patients; 
they found that SVR12 by ITT was equal in both subgroups of patients, 97.3% and 97.5%, 
respectively. This confirmed the importance of a highly controlled environment on the clinical 
follow up of patients, such as clinical trials, to obtain the best results in the use of DAAs in HCV 
patients. In our study, no significant differences were observed in the effectiveness in relation to 
baseline mental disorder compared to nonpsychiatric patients, except in patients with bipolar 
disorder, although it is important to note that only 8 patients had this psychiatric diagnosis in the 
analyzed population. Within the subgroup of psychiatric patients, no differences have been observed 
in the DAAs effectiveness based on the baseline psychiatric diagnosis, a number of psychiatric 
diagnoses or number of psychiatric medications per patient. Other baseline variables of psychiatric 
patients, such as the presence of cirrhosis, previous treatments or viral genotype, have not influenced 
the effectiveness of antiviral treatment (multivariate analysis). 
A high and very similar global therapeutic safety has been observed in the group of psychiatric 
patients vs nonpsychiatric patients, with very similar incidence rates of mild, moderate, or severe 
adverse effects reported by the patients, as well as visits to the emergency room or treatment 
withdrawals secondary to the development of serious adverse effects. These results are in line with 
those reported but limited to the use of glecaprevir/pibrentasvir in psychiatric patients.55 It is also 
important to highlight the results of DAAs neuropsychiatric safety in this study, with a very low 
incidence in psychiatric patients and because of the parallelism of the symptoms in the two 
subgroups of patients analyzed. Only a higher incidence of mild anxiety has been observed in 
psychiatric vs nonpsychiatric patients, although the difference was not considered clinically 
significant. These safety results of the psychiatric symptomatology corroborate those observed in 
previous studies, at the level of the evaluation on anxiety or depression, fatigue and mood, cognitive 
state, or sleep disturbances.56‐60 In addition, patients with psychiatric disorders, in this study, have 
not developed decompensation of their mental illness during DAAs treatment, as other authors have 
also evaluated but limited to DAAs treatments based on ribavirin.61 
Although this study presents the strengths of being prospectiveand includes a large number of 
patients in both treatment subgroups,we would like to emphasize that patients have not undergone 
anevaluation through validated scales on psychiatric symptoms before,during, or after antiviral 
treatment. 
As final conclusions, we can highlight the high effectiveness andsafety of DAAs in psychiatric 
HCV‐infected patients. However, ef-fectiveness is slightly lower in psychiatric patients as a result 
oftracking losses in the subgroup of patients with mental disorderssecondary to multiple drug use. 
This fact supports the need for in-tegrated and multidisciplinary health care teams that guarantee 
theclinical follow up of patients throughout the health care process. Norelevant rates of psychiatric 
hospital admission or urgent psychiatricattention were observed during antiviral treatment, so it is 
deducedthat DAAs do not significantly influence the symptomatology of thepsychiatric disorder. 
Furthermore, no clinically significant differenceshave been observed in relation to adherence to 
antiviral treatment orincidence of clinically significant interactions 
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